Kexing Biopharm and IQVIA Form Strategic Alliance for Clinical Development and Commercialization

Kexing Biopharm has formed a strategic alliance with IQVIA, a global leader in clinical research services, commercial analytics, and healthcare intelligence. The partnership aims to accelerate the global clinical development, regulatory approval, and commercialization of Kexing's innovative drugs and biosimilars, focusing on the European and other regulated international markets. Kexing has made significant strides towards internationalization through its unique globalization platform, which integrates advanced R&D capabilities with agile commercial execution.

Kexing Biopharm, a leading biopharmaceutical company listed on the Shanghai Stock Exchange (688136.SH), has entered into a strategic partnership with IQVIA (NYSE:IQV), a global leader in clinical research services, commercial insights, and healthcare intelligence. This alliance aims to accelerate the global clinical development, regulatory approval, and commercialization of Kexing's innovative drugs and biosimilars, with a strategic focus on Europe and other regulated international markets [1].

Kexing Biopharm has been making significant strides towards internationalization by building a unique globalization platform that integrates advanced R&D capabilities with agile commercial execution. The company has successfully facilitated the overseas market entry of several high-quality pharmaceutical products, including its in-licensed nab-paclitaxel, which has achieved rapid approval and launch in several key jurisdictions [1].

The partnership leverages IQVIA's deep expertise in global clinical trial design, regulatory strategy, and data-driven insights. By combining Kexing's innovative product pipeline with IQVIA's global operational infrastructure, the two companies aim to enhance trial efficiency and enable faster access to international markets. This collaboration is expected to significantly strengthen Kexing's global development capabilities and accelerate its transition towards becoming an international biopharmaceutical innovator [1].

During the signing ceremony, Mr. Brian Mi, President of IQVIA Asia Pacific, highlighted Kexing's rapid progress in overseas commercialization and product innovation, stating that the collaboration would unlock new opportunities for both parties. Mr. Yanqing Zhao, CEO of Kexing Biopharm, emphasized that IQVIA's global clinical data resources, patient insights, and regulatory knowledge will play a critical role in optimizing development strategy, improving success rates, and accelerating global registration timelines [1].

Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production, and sales of recombinant protein drugs and microecological preparations. Focusing on antiviral therapy and the treatment of tumor, autoimmune, metabolic diseases, degenerative diseases, and other therapeutic fields, it is dedicated to building cutting-edge biotechnology platforms for new protein, new antibody, nucleic acid, and other drugs. The strategic alliance reflects Kexing Biopharm's long-term commitment to international expansion through scientific rigor, efficient execution, and strong partnerships [1].

Moving forward, Kexing will continue to deepen global collaborations to bring more high-quality Chinese pharmaceutical innovations to patients around the world.

References:
[1] https://www.prnewswire.com/news-releases/kexing-biopharm-enters-strategic-partnership-with-iqvia-to-accelerate-global-expansion-302526319.html